Omid Hamid - Publications, H-index & Citations

Back

Omid Hamid

medical oncology

96H-index

860Paper Count

8.3WCitation Count

Published Papers 145

Publication Date

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

Nature Communications

IF15.7

2026-02-16

OAAI

O. Hamid; V. Ekström-Rydén; I. Mehmi; D. Wang; M. Patel; S. Alsaqal; S. Irenaeus; C. Nordström; LC Sandin; H. Grauers Wiktorin; T. Lövgren; E. Eriksson; J. Leja-Jarblad; A. Loskog; GJ Ullenhag

Save

Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses

Human Vaccines and Immunotherapeutics

IF3.5

2025-12-31

PREAI

Kazerani, Maryam; Mahov, Simeon; Foley, Joslyn; Merin, Noah M.; Choi, So Yung; Lownik, Joseph; Xu, Alexander M.; Milshteyn, Larry; Villamejor, Anton Luis; Nadri, Maimoona; Nguyen, Nathalie; Kazemian, Elham; Hamid, Omid; Darrah, Justin; Gong, Jun; Paquette, Ronald; Vescio, Robert; Mehmi, Inderjit; Tourtellotte, Warren G.; Ramanujan, V. Krishnan; Reckamp, Karen L.; Figueiredo, Jane C.; Merchant, Akil

Save

Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

eClinicalMedicine

IF10

2025-10-07

OAAI

Jessica S.W. Borgers; Douglas B. Johnson; Elisabeth Livingstone; Dirk Schadendorf; Elizabeth I. Buchbinder; Lauren E. Haydu; Laura Gohil; William A. Robinson; Inderjit Mehmi; Omid Hamid; Michelle Ferreira; April K.S. Salama; Florentia Dimitriou; Matteo S. Carlino; Georgina V. Long; Paolo A. Ascierto; Ester Simeone; Yana G. Najjar; Geke A.P. Hospers; Jacob Choi; Sunandana Chandra; Jeffrey D. Wayne; Carlos I.R. García; Wen Xu; Céleste Lebbé; Laetitia Da-Meda; Victoria Atkinson; Meredith Mckean; Andrea Forschner; Elliot A. Asare; Antonios Daletzakis; Jolyn S. Taylor; Frédéric Amant; Katy K. Tsai; Zeynep Eroglu; John B.A.G. Haanen; Isabella C. Glitza de Oliva

Save

Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients

ONCOLOGIST

IF4.2

2025-10-01

OAAI

Lim, Tristan L.; Montazeri, Kamaneh; Wehrenberg-Klee, Eric; Desilets, Antoine; Seedor, Rino; Orloff, Marlana; Sato, Takami; Caplan, Michael; El-Ashmawy, Mariam; Izar, Benjamin; Khan, Shaheer; Mehmi, Inderjit; Lawless, Aleigha; Hong, Theodore S.; Hamid, Omid; Carvajal, Richard D.; Shoushtari, Alexander; Sullivan, Ryan J.

Save

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

Nature Medicine

IF50

2025-09-24

OAAI

Georgina V. Long; Nitya Nair; Daniel Marbach; Richard A. Scolyer; Sabine Wilson; Denise Cotting; Nicolas Staedler; Rodabe N. Amaria; Paolo Antonio Ascierto; Ahmad A. Tarhini; Caroline Robert; Omid Hamid; Caroline Gaudy-Marqueste; Celeste Lebbe; Eva Munoz-Couselo; Alexander M. Menzies; Cecile Pages; Giuseppe Curigliano; Mario Mandala; Nikki Jessop; Uwe Bader; Maurizio Perdicchio; Volker Teichgräber; Merlind Muecke; Christoph Markert; Christian Blank

Save

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors

ONCOLOGIST

IF4.2

2025-07-01

PREAI

Gutierrez, Martin E.; Tang, Shou-Ching; Powderly, John D.; Balmanoukian, Ani S.; Hoyle, Paul E.; Dong, Zhiwan; Cheng, Lulu; Gong, Xiaohua; Janik, John E.; Bourayou, Nawel; Hamid, Omid

Save

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors

ONCOLOGIST

IF4.2

2025-07-01

PREAI

Powderly II, John D.; Gutierrez, Martin E.; Balmanoukian, Ani S.; Hoyle, Paul E.; Dong, Zhiwan; Cheng, Lulu; Chen, Xuejun; Janik, John E.; Bourayou, Nawel; Hamid, Omid

Save

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis

FUTURE ONCOLOGY

IF2.6

2025-05-26

OAAI

Menzies, Alexander M.; Long, Georgina V.; Kohn, Amiee; Tawbi, Hussein; Webe, Jeffrey; Flaherty, Keith; McArthur, Grant A.; Ascierto, Paolo A.; Pfluger, Yanina; Lewis, Karl; Tsai, Katy K.; Hamid, Omid; Prenen, Hans; Fein, Luis; Wang, Erjian; Guenzel, Carolin; Zhang, Fan; Kleh, Joseph F.; di Pietro, Alessandra; Davies, Michael A.

Save

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

CELL REPORTS MEDICINE

IF10.6

2025-04-01

OAAI

Sacco, Joseph J.; Kirk, Peter; Leach, Emma; Shoushtari, Alexander N.; Carvajal, Richard D.; Britton-Rivet, Camille; Khakoo, Sophie; Collins, Laura; de la Cruz-Merino, Luis; Eroglu, Zeynep; Ikeguchi, Alexandra P.; Nathan, Paul; Hamid, Omid; Butler, Marcus O.; Stanhope, Sarah; Ranade, Koustubh; Sato, Takami

Save

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products

TRANSPLANTATION AND CELLULAR THERAPY

IF4.4

2025-03-01

PREAI

Lievense, Justin J.; Nijenhuis, Cynthia; Jedema, Inge; Jonker-Hoogerkamp, Arendien; Moyers, Justin T.; Hamid, Omid; Beijnen, Jos H.; Haanen, John B. A. G.; Nuijen, Bastiaan

Save

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

EUROPEAN JOURNAL OF CANCER

IF7.1

2025-01-01

OAAI

Dimitriou, Florentia; Orloff, Marlana M.; Hein, Erica C. Koch; Cheng, Phil F.; Hughes, Isaac F.; Simeone, Ester; Montazeri, Kamaneh; Grover, Piyush; Mehmi, Inderjit; Gerard, Camille L.; Gaudy-Marqueste, Caroline; Grob, Jean-Jacques; Michielin, Olivier; Hamid, Omid; V. Long, Georgina; Sullivan, Ryan; Kapiteijn, Ellen; Johnson, Douglas B.; Ascierto, Paolo A.; Joshua, Anthony M.; Carvajalh, Richard D.; Butler, Marcus O.; Hasselu, Jessica C.; Dummer, Reinhard

Save

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY

IF65.4

2025-01-01

PREAI

Amaral, T.; Ottaviano, M.; Arance, A.; Blank, C.; Chiarion-Sileni, V.; Donia, M.; Dummer, R.; Garbe, C.; Gershenwald, J. E.; Gogas, H.; Guckenberger, M.; Haanen, J.; Hamid, O.; Hauschild, A.; Hoeller, C.; Lebbe, C.; Lee, R. J.; Long, G., V; Lorigan, P.; Couselo, E. Munoz; Nathan, P.; Robert, C.; Romano, E.; Schadendorf, D.; Sondak, V; Suijkerbuijk, K. P. M.; van Akkooi, A. C. J.; Michelin, O.; Ascierto, P. A.

Save

NRF-1 transcription factor regulates expression of an innate immunity checkpoint, CD47, during melanomagenesis

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-12-17

OAAI

Makwana, Kuldeep; Velazquez, Edwin J.; Marzese, Diego M.; Smith, Bethany; Bhowmick, Neil A.; Faries, Mark B.; Hamid, Omid; Boiko, Alexander D.

Save

Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2024-10-09

OAAI

Seedor, Rino S.; Aplin, Andrew E.; Bertolotto, Corine; Carvajal, Richard D.; Deacon, Nigel; Doble, Katie; Hamid, Omid; Haq, Rizwan; Kadosh, Miriam; Khan, Shaheer; Kraska, Jacqueline; Lutzky, Jose; McKean, Meredith; Montazeri, Kamaneh; Moser, Justin; Onken, Michael; Orloff, Marlana; Sacco, Joseph J.; Smalley, Keiran; Selig, Sara M.

Save

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Friedman, C.; Williams, A. De Burgh; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Garcia, V. Moreno; Johnson, M. L.; Davar, D.; Martin-Liberal, J.; Roxburgh, P.; Moore, K. N.; Olson, D.; Rottey, S.; Kirk, P. B.; Yuan, Y.; Marshall, S.; Yeku, O.

Save

Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; Nathan, P.; Piulats Rodriguez, J. M.; Shaw, H.; Davar, D.; Han, C.; Middleton, M. R.; Thistlethwaite, F.; Peck, F.; Ranade, K.; Sato, T.

Save

A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Wentzel, K.; Peguero, J.; Kummar, S.; Lorusso, P.; Mehnert, J. M.; Spira, A. I.; Naing, A.; Hamid, O.; Mehmi, I.; Benhadji, K.; Alland, L.; Hu, X.; Xiao, H.; Bao, X.; Chen, J.; Gong, Y.; Liu, X. S.

Save

A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Hamid, O.; Ryden, V.; Mehmi, I.; Wang, D.; Patel, M.; Krause, J.; Sandin, L. C.; Wiktorin, H. Grauers; Lovgren, T.; Eriksson, E.; Jarblad, J. Leja; Loskog, A.; Ullenhag, G. J.

Save

Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Robert, C.; Carlino, M.; McNeil, C.; Ribas, A.; Schachter, J.; Nyakas, M.; Kee, D.; Petrella, T.; Blaustein, A.; Lotem, M.; Arance, A. M.; Daud, A.; Hamid, O.; Larkin, J.; Yao, L.; Singh, R.; Lal, R.; Long, G.

Save

Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Thomas, Sajeve S.; Chesney, Jason A.; Hamid, Omid; In, Gino K.; Shoushtari, Alexander N.; Samhouri, Yazan; Hari, Parameswaran; Ramsingh, Giridharan; Prabhakar, Prakash; Mclaughlin, Lauren; Warner, Allison Betof

Save

Research Directions